These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 837950)

  • 1. Correlation between tumour stage, tumour grade, and immunocompetence in patients with carcinoma of the bladder and prostate.
    Adolphs HD; Steffens L
    Eur Urol; 1977; 3(1):23-5. PubMed ID: 837950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the immunocompetance of patients with transitional cell carcinoma of the bladder.
    Adolphs HD; Steffens L
    Urol Res; 1977; 5(1):29-33. PubMed ID: 855056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of host immunocompetence in urologic cancer patients.
    Catalona WJ; Smolev JK; Harty JI
    J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
    Genega EM; Hutchinson B; Reuter VE; Gaudin PB
    Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma.
    Catalona WJ; Chretien PB
    J Urol; 1973 Nov; 110(5):526-8. PubMed ID: 4750895
    [No Abstract]   [Full Text] [Related]  

  • 6. Carcinoembryonic antigen in patients with urologic cancers.
    Guinan P; Ablin RJ; Barakat H; John T; Sadoughi N; Bush IM
    Urol Res; 1973 Oct; 1(3):101-5. PubMed ID: 4804082
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    Packeiser EM; Hewicker-Trautwein M; Thiemeyer H; Mohr A; Junginger J; Schille JT; Murua Escobar H; Nolte I
    PLoS One; 2020; 15(3):e0230272. PubMed ID: 32168360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
    Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
    Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association of adenocarcinoma of the prostate with transitional carcinoma of the bladder].
    de Boccard GA; Chatelanat F; Graber P
    Helv Chir Acta; 1985 Sep; 52(3-4):533-4. PubMed ID: 4066384
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
    Mai KT; Yazdi HM; Farmer J
    Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative study of the cases of transitional cell carcinoma of the prostate and prostatic involvement of transitional cell carcinoma of the urinary bladder. I) Transitional cell carcinoma of the prostate].
    Takai K; Kakizoe T; Tobisu K; Matsumoto K; Kishi K
    Nihon Hinyokika Gakkai Zasshi; 1987 Aug; 78(8):1365-71. PubMed ID: 3437644
    [No Abstract]   [Full Text] [Related]  

  • 12. Defective monocyte chemotactic response in genitourinary carcinoma.
    Brosman S; Hausman MS
    Urology; 1974 Aug; 4(2):129-34. PubMed ID: 4851277
    [No Abstract]   [Full Text] [Related]  

  • 13. Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment.
    Androulakakis PA; Schneider HM; Jacobi GH; Hohenfellner R
    Br J Urol; 1986 Apr; 58(2):153-6. PubMed ID: 3697629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function.
    Bean MA; Schellhammer PS; Herr HW; Pinsky CM; Whitmore WF
    Natl Cancer Inst Monogr; 1978 Dec; (49):111-4. PubMed ID: 155219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexisting adenocarcinoma of prostate in patients undergoing cystoprostatectomy for bladder cancer.
    Winfield HN; Reddy PK; Lange PH
    Urology; 1987 Aug; 30(2):100-1. PubMed ID: 3617289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic aspects of malignancy. II. Host immunocompetence and relationship to the clinical stage in patients with prostatic cancer.
    Ablin RJ; Guinan PD; Rios ER
    Allergol Immunopathol (Madr); 1976; 4(4):247-54. PubMed ID: 983900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic features of genitourinary cancer.
    Javadpour N
    Urology; 1973 Aug; 2(2):103-8. PubMed ID: 4129366
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostatic urothelial location of a tumor of the bladder].
    Coulange C; Lechevallier E; de Fromont M
    Prog Urol; 1997 Feb; 7(1):128-31. PubMed ID: 9116731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo skin test in carcinoma bladder.
    Gupta NP; Rajagopal V; Malaviya AN; Singh SM
    Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):163-5. PubMed ID: 6545227
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed cutaneous hypersensitivity in patients with prostatic adenocarcinoma.
    Huus JC; Kursh ED; Poor P; Persky L
    J Urol; 1975 Jul; 114(1):86-7. PubMed ID: 1142506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.